As of Aug 28
| -0.17 / -0.47%|
The 8 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 44.00, with a high estimate of 53.00 and a low estimate of 34.00. The median estimate represents a +22.39% increase from the last price of 35.95.
The current consensus among 11 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.